Monopar Therapeutics Total Debt Growth & History (MNPR)
Monopar Therapeutics's total debt was $245,489 for fiscal 2025.
View full Monopar Therapeutics company overviewMonopar Therapeutics annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $245,489 | $245,489 | — |
| 2024 | 2024-12-31 | $0 | −$8,408 | — |
| 2023 | 2023-12-31 | $8,408 | −$48,582 | −85.25% |
| 2022 | 2022-12-31 | $56,990 | $56,990 | — |
| 2021 | 2021-12-31 | $0 | — | — |
Monopar Therapeutics quarterly total debt
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $205,663 | $91,923 | +80.82% |
| Q1 2026 | 2026-03-31 | $230,425 | $222,173 | +2692.35% |
| Q4 2025 | 2025-12-31 | $245,489 | $245,489 | — |
| Q3 2025 | 2025-09-30 | $102,236 | $102,236 | — |
| Q2 2025 | 2025-06-30 | $113,740 | $113,740 | — |
| Q1 2025 | 2025-03-31 | $8,252 | — | — |
| Q4 2024 | 2024-12-31 | $0 | −$8,408 | — |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $0 | $0 | — |
| Q4 2023 | 2023-12-31 | $8,408 | −$48,582 | −85.25% |
| Q3 2023 | 2023-09-30 | $0 | −$68,651 | — |
| Q2 2023 | 2023-06-30 | $0 | −$80,125 | — |
| Q1 2023 | 2023-03-31 | $0 | −$51,315 | — |
| Q4 2022 | 2022-12-31 | $56,990 | $56,990 | — |
| Q3 2022 | 2022-09-30 | $68,651 | $68,651 | — |
| Q2 2022 | 2022-06-30 | $80,125 | $80,125 | — |
| Q1 2022 | 2022-03-31 | $51,315 | $51,315 | — |
| Q4 2021 | 2021-12-31 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $0 | — | — |
| Q2 2021 | 2021-06-30 | $0 | — | — |
| Q1 2021 | 2021-03-31 | $0 | — | — |
Monopar Therapeutics total debt trends
Between the periods ended 2021-12-31 and 2025-12-31, Monopar Therapeutics's total debt increased from $0 to $245,489, a change of $245,489. The latest reported quarter, Q2 2026, shows $205,663.
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monopar Therapeutics source filings ↗